370 related articles for article (PubMed ID: 29688063)
1. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer.
Rastegar R; Akbari Javar H; Khoobi M; Dehghan Kelishadi P; Hossein Yousefi G; Doosti M; Hossien Ghahremani M; Shariftabrizi A; Imanparast F; Gholibeglu E; Gholami M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):207-216. PubMed ID: 29688063
[TBL] [Abstract][Full Text] [Related]
2. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
3. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
6. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
[TBL] [Abstract][Full Text] [Related]
7. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
[TBL] [Abstract][Full Text] [Related]
8. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
9. pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer.
Yuan JD; ZhuGe DL; Tong MQ; Lin MT; Xu XF; Tang X; Zhao YZ; Xu HL
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):302-313. PubMed ID: 29301415
[TBL] [Abstract][Full Text] [Related]
10. Zwitterionic Polymer Micelles with Dual Conjugation of Doxorubicin and Curcumin: Synergistically Enhanced Efficacy against Multidrug-Resistant Tumor Cells.
Zhao G; Sun Y; Dong X
Langmuir; 2020 Mar; 36(9):2383-2395. PubMed ID: 32036662
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
13. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
14. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
[TBL] [Abstract][Full Text] [Related]
15. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
16. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of A-B-C-type amphiphilic copolymer on reversal of drug resistance in MCF-7/ADR breast carcinoma.
Zhang L; Lu J; Qiu L
Int J Nanomedicine; 2016; 11():5205-5220. PubMed ID: 27785023
[TBL] [Abstract][Full Text] [Related]
18. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
19. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer.
Zhao X; Chen Q; Liu W; Li Y; Tang H; Liu X; Yang X
Int J Nanomedicine; 2015; 10():257-70. PubMed ID: 25565818
[TBL] [Abstract][Full Text] [Related]
20. Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin‑resistant breast cancer cells.
Wen C; Fu L; Huang J; Dai Y; Wang B; Xu G; Wu L; Zhou H
Mol Med Rep; 2019 Jun; 19(6):5162-5168. PubMed ID: 31059026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
